- Home
- PHAR vs NMCO Comparison
PHAR vs NMCO Comparison
Compare PHAR & NMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAR | NMCO |
|---|---|---|
| Founded | 1988 | 2019 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 560.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PHAR | NMCO |
|---|---|---|
| Price | $18.43 | $10.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $38.00 | N/A |
| AVG Volume (30 Days) | 26.2K | ★ 207.6K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.43% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $362,274,000.00 | N/A |
| Revenue This Year | $25.19 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $3,324.60 | ★ N/A |
| Revenue Growth | ★ 26.78 | N/A |
| 52 Week Low | $7.50 | $8.52 |
| 52 Week High | $19.05 | $11.64 |
Technical Indicators
Market Signals| Indicator | PHAR | NMCO |
|---|---|---|
| Relative Strength Index (RSI) | 57.05 | 56.68 |
| Support Level | $17.76 | $10.48 |
| Resistance Level | $18.72 | $10.65 |
| Average True Range (ATR) | 0.64 | 0.09 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 75.20 | 79.17 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.